Europe approves Opdivo-Yervoy immuno combination for melanoma

May 12, 2016 News BioVox

Bristol-Myers Squibb Co. (NYSE:BMY) said the European Commission approved Opdivo nivolumab in combination with Yervoy ipilimumab to treat advanced melanoma in adults independent of BRAF mutation status. The company said it is the first combination of two immuno-oncology therapies to be approved in the EU.

BMS markets both drugs. Opdivo, a human IgG4 against PD-1, is approved in the EU as monotherapy to treat locally advanced melanoma, and to treat advanced or metastatic squamous non-small cell lung cancer (NSCLC). Yervoy, a human mAb against CTLA-4 (CD152), is also approved as monotherapy in the EU to treat advanced melanoma.


Avatar photo
BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe

* indicates required

Intuit Mailchimp